youtube_live
Q3 2026 earnings • released • EPS beat +283.98%
See resultschevron_right
EWTX:NASDAQ
Edgewise Therapeutics Inc
$38.87
arrow_upward
+3.57%(+1.34) 1D
$38.87
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 5, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EWTX...
Open
$43.00
High
$43.25
Low
$36.72
Mkt. cap
4.22B
Avg. vol.
1.49M
Volume
5.04M
52-wk high
$48.50
52-wk low
$16.70
EPS
-$1.85
Beta
0.39
Shares outstanding
108.60M
No. of employees
127
Open
$43.00
High
$43.25
Low
$36.72
Mkt. cap
4.22B
Avg. vol.
1.49M
Volume
5.04M
52-wk high
$48.50
52-wk low
$16.70
EPS
-$1.85
Beta
0.39
Shares outstanding
108.60M
No. of employees
127
News stories
From web sources and news partners
Investing.com Canada
·
7 hours ago
Raymond James raises Edgewise Therapeutics price target on FDA feedback By Investing.com
Investing.com
·
9 hours ago
Edgewise submits phase 3 protocol for heart drug EDG-7500
Traders Union
·
1 day ago
Edgewise Therapeutics announces Q3 2026 financial results: Will EWTX hold $36.7 support?
GuruFocus
·
1 day ago
Edgewise Therapeutics Inc Reports Q3 2026 Net Income of $1.166 B
About Edgewise Therapeutics Inc
CEO-
Employees127
Founded2017
HeadquartersBoulder, Colorado, United States
SectorHealth Care
IndustryPharmaceutical industry
Websiteedgewisetx.com
Analyst ratings
Based on 12 analysts giving stock ratings to EWTX in the past 3 months
Strong buy
Buy
10
Hold
2
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for EWTX in the last 3 months.
Highest
Current $38.87
$85.00 (+118.68%)
Average
$54.30 (+39.70%)
Lowest
$36.00 (-7.38%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Martin Auster Raymond James | Buy | Reiterated | $85.00 | +118.7% | 11/05/2026 |
James Condulis Stifel Nicolaus | Hold | Reiterated | $36.00 | -7.4% | 11/05/2026 |
Laura Chico Wedbush | Buy | Maintained | $51.00 | +31.2% | 11/05/2026 |
Leonid Timashev RBC Capital | Buy | Reiterated | $59.00 | +51.8% | 11/05/2026 |
Lander Egana Gorrono H.C. Wainwright | Buy | Maintained | $57.00 | +46.6% | 11/05/2026 |
Cory Kasimov Evercore ISI | Buy | Maintained | $55.00 | +41.5% | 11/05/2026 |
Unknown Analyst William Blair | Buy | Initiated | $53.00 | +36.4% | 10/15/2026 |
Sharon Zackfia William Blair | Buy | Initiated | $53.00 | +36.4% | 10/15/2026 |
Yasmeen Rahimi Piper Sandler | Buy | Maintained | $51.00 | +31.2% | 10/13/2026 |
Srikripa Devarakonda Truist Financial | Buy | Reiterated | - | - | 09/23/2026 |
Paul Choi Goldman Sachs | Hold | Maintained | $36.00 | -7.4% | 09/22/2026 |
Joseph Schwartz Leerink Partners | Buy | Reiterated | - | - | 09/23/2026 |
Tessa Romero J.P. Morgan | Buy | Reiterated | $60.00 | +54.4% | 08/20/2026 |
Joseph Pantginis H.C. Wainwright | Buy | Maintained | $45.00 | +15.8% | 08/06/2026 |
Mazahir Alimohamed Oppenheimer | Buy | Initiated | $51.00 | +31.2% | 07/09/2026 |
Debjit Chattopadhyay Guggenheim | Buy | Maintained | $51.00 | +31.2% | 07/06/2026 |
Unknown Analyst Guggenheim | Buy | Maintained | $41.00 | +5.5% | 06/02/2026 |
Unknown Analyst Goldman Sachs | Hold | Maintained | $20.00 | -48.5% | 05/11/2026 |
David Nierengarten Wedbush | Buy | Maintained | $46.00 | +18.3% | 05/08/2026 |
Last report
Nov 4, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$9.65 / $2.51
+283.98%beat
arrow_upward
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | - | - | - | - |
Cost of goods sold | - | - | - | - |
Cost of revenue | - | - | - | - |
Research and development expenses | 37.48M | 43.59M | 42.65M | 47.55M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 9.38M | 12.38M | 11.46M | 14.40M |
Operating expense | 46.86M | 55.98M | 54.12M | 61.94M |
Total operating expenses | 46.86M | 55.98M | 54.12M | 61.94M |
Operating income | -46.86M | -55.98M | -54.12M | -61.94M |
Other non operating income | - | - | - | - |
EBT including unusual items | -40.67M | -50.22M | -49.01M | -57.33M |
EBT excluding unusual items | -40.67M | -50.22M | -49.01M | -57.33M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -40.67M | -50.22M | -49.01M | -57.33M |
Net profit margin | - | - | - | - |
Earnings per share | -0.39 | -0.47 | -0.46 | -0.53 |
Interest and investment income | 6.19M | 5.76M | 5.10M | 4.62M |
Interest expense | - | - | - | - |
Net interest expenses | 6.19M | 5.76M | 5.10M | 4.62M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -46.34M | -55.45M | -53.58M | -61.40M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events